Jian Li, PhD

Dr Li is a Fellow of the Australian Academy of Science (AAS), the Australian Academy of Health and Medical Sciences (AAHMS), and the American Academy of Microbiology (AAM). He is also recognized as a Clarivate® Highly Cited Researcher in pharmacology and toxicology (2015-2017, 2022). His research focuses on antimicrobial chemotherapy (including phage pharmacology) and drug discovery, particularly in pharmacokinetics, pharmacodynamics, toxicodynamics, microbiology, systems pharmacology, and toxicity. Dr Li has 453 publications (including 10 book chapters) with 31,913 citations and an h-index of 85. He has delivered more than 110 invited conference talks, seminars and public lectures at universities, institutes, the Food and Drug Administration, and pharmaceutical companies internationally. His research led to the first scientifically-based dosing recommendations for colistin, which have been employed by the European Medicines Agency and improved clinical practice worldwide. Dr Li’s novel antibiotic drug QPX9003 has been developed from concept in his laboratory to clinical trials and licensed to Qpex Biopharma and Brii Biosciences. Since 2004 Dr Li has been awarded 63 grants (including 13 National Institutes of Health [NIH] R01) from various funding agencies and pharmaceutical companies. He is President of the International Society of Anti-Infective Pharmacology (2022-2024), Editor-in-Chief of the International Journal of Antimicrobial Agents and the first book on polymyxins (Springer Nature, 2019; >68,000 downloads), and an invited reviewer for approximately 200 international journals.

(Updated July 18, 2024)